MENLO PARK, Calif.–(BUSINESS WIRE)–GRAIL, Inc., a healthcare company whose mission is to detect cancer early, when it can be cured, today announced the appointment of Hal Barron, MD, and Hans Bishop to its Board of Directors.
“We are delighted to welcome Hal and Hans to our Board. They are both known for being exceptional leaders who are committed to making an impact for people suffering from disease,” said Jennifer Cook, Chief Executive Officer of GRAIL. “We look forward to benefiting from their significant scientific and corporate experience as we continue on our path to develop early detection products and alleviate the global cancer burden.”
Hal Barron is globally recognized for his clinical and scientific leadership. He is the Chief Scientific Officer and President of R&D at GlaxoSmithKline (GSK). Prior to his role at GSK, Dr. Barron was Calico’s President of R&D. Previously, he was Executive Vice President, Head of Global Product Development, and Chief Medical Officer of Roche Pharmaceuticals. Prior to this, he was Senior Vice President and Chief Medical Officer of Genentech. Dr. Barron is also Associate Adjunct Professor of Epidemiology and Biostatistics at the University of California, San Francisco. Dr. Barron holds a bachelor’s degree in physics from Washington University in St. Louis and a medical degree from Yale University.
Hans Bishop has more than 30 years of experience in the biotechnology industry. Mr. Bishop currently serves on the Board of Directors of Celgene and Agilent Technologies. Mr. Bishop founded Juno Therapeutics in 2013 and served as its President and Chief Executive Officer until the company was acquired by Celgene in March 2018. Prior to this, he served as an Executive in Residence at Warburg Pincus. Earlier, he was Executive Vice President and Chief Operating Officer for Dendreon, Inc. He also previously served as President of Specialty Medicine at Bayer Healthcare, Senior Vice President of Global Commercial Operations at Chiron Corporation, and Vice President and General Manager of European Biopharmaceuticals. Mr. Bishop holds a bachelor’s degree in chemistry from Brunel University in London.
GRAIL is a healthcare company whose mission is to detect cancer early, when it can be cured. GRAIL is using the power of high-intensity sequencing, population-scale clinical studies, and state-of-the-art computer science and data science to enhance the scientific understanding of cancer biology, and to develop and commercialize pioneering products for the early detection of cancer. The company is located in Menlo Park, California and Hong Kong. It is supported by leading global investors and pharmaceutical, technology, and healthcare companies. For more information, please visit www.grail.com.